Progression-free survival is a surrogate for survival in advanced colorectal cancer

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5218-5224

  Buyse, Marc ^a   Burzykowski, Tomasz ^a   Carroll, Kevin ^a   Michiels, Stefan ^a   Sargent, Daniel J ^a   Miller, Langdon L ^a   Elfring, Gary L ^a   Pignon, Jean Pierre ^a   Piedbois, Pascal ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FLUOROURACIL; HUMANS; LEUCOVORIN;

EID: 36849078044     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.8836     Document Type: Article

References (29)

1. Buyse M, Thirion P, Carlson RW, et al: Tumour response to first line chemotherapy improves the survival of patients with advanced colorectal cancer. Lancet 356:373-378, 2000
2. Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated metaanalysis. J Clin Oncol 22:3766-3775, 2004
3. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
6. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
7. Cunningham D, Zalcberg JR, Rath U, et al: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961-965, 1996
8. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16:228a, 1997 (abstr 801)
9. Cocconi G, Cunningham D, Van Cutsem E, et al: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16:2943-2952, 1998
10. Cox DR: Regression models and life tables (with discussion). JR Stat Soc B 34:187-220, 1972
11. Buyse M, Molenberghs G, Burzykowski T, et al: The validation of surrogate endpoints in metaanalyses of randomised experiments. Biostatistics 1:49-67, 2000
12. Burzykowski T, Molenberghs G, Buyse M Evaluation of Surrogate Endpoints. Heidelberg, Germany, Springer Verlag, 2005
13. Burzykowski T, Molenberghs G, Buyse M, et al: Validation of surrogate endpoints in multiple randomised clinical trials with failure-time endpoints. J Royal Stat Soc C (Applied Statist) 50:405-422, 2001
14. Borner MM, Castiglione M, Bacchi M, et al: The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Ann Oncol 9:535-541, 1998
15. Bobbio-Pallavicini E, Porta C, Moroni M, et al: Folinic acid does improve 5-fluorouracil activity in vivo: Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 5:52-55, 1993
16. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
17. Cunningham D, Humblet Y, Siena S, et al: A randomised comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
18. Louvet C, de Gramont A, Tournigand C, et al: Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91:2033-2038, 2001
19. Fleming TR, DeMets DL: Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 125:605-613, 1996
20. Sargent D, Wieand S, Haller DG, et al: Disease-free survival (DFS) vs overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
21. Burzykowski T, Molenberghs G, Buyse M, et al: The validation of surrogate endpoints using data from randomised clinical trials: A case-study in advanced colorectal cancer. J Royal Statist Soc A 167:103-124, 2004
22. Michiels S, Piedbois P, Burdett S, et al: Metaanalysis when only the median survival times are known: A comparison with individual patient data results. Intl J Technol Assess Health Care 21:119-125, 2005
23. Johnson KR, Ringland C, Stokes BJ, et al: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 7:741-746, 2006
24. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
25. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
26. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441-9442, 2005
27. Di Leo A, Bleiberg H, Buyse M: Is overall survival a realistic primary endpoint in advanced colorectal cancer? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with irinotecan. Ann Oncol 14:545-549, 2004
28. Di Leo A, Bleiberg H, Buyse M: Overall survival is not a realistic endpoint for clinical trials in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 21:2045-2047, 2003
29. US Food & Drug Administration: Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. www.fda.gov/cder/ guidance/6592dft.htm